Eleni Timotheadou

Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose

Michelle Harrison, Eva Obermueller, Nick Maisey et al. · Journal of Clinical Oncology · 2007 · 247 citations · Full text

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

Florentia Fostira, Marianthi Tsitlaidou, Christos Papadimitriou et al. · Breast Cancer Research and Treatment · 2012 · 119 citations

Brca1 Mutations, Breast Oncology, Cancer Epidemiology +10

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

George Fountzilas, Christos Valavanis, Vassiliki Kotoula et al. · Journal of Translational Medicine · 2012 · 100 citations · Full text

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

George Fountzilas, Dimosthenis Skarlos, Urania Dafni et al. · Annals of Oncology · 2005 · 99 citations · Full text

Surgical Oncology, Breast Oncology, Medicine +5

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Aristotelis Bamias, Urania Dafni, Alexandra Karadimou et al. · Annals of Oncology · 2012 · 97 citations

Surgical Oncology, Urology, He 16/03 +7